AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28971986 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person counseling (IPC)
Number of subjects: 781
Study 28971986 — intervention group
Group type: COMPARATOR
Intervention: Telephone counseling (TC)
Number of subjects: 781
Study 28971986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost barriers
Number of subjects: 781
Study 28971986 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived comparative mutation risk
Number of subjects: 781
Study 26541812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool Little Kids Online (intervention group)
Number of subjects: 385
Study 26541812 — intervention group
Group type: COMPARATOR
Intervention: Delayed access (control group)
Number of subjects: 385
Study 22450257 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric Training Group (PTG)
Number of subjects: 45
Study 22450257 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 45
Study 21414045 — intervention group
Group type: EXPERIMENTAL
Intervention: HVP (5-15 g per day)
Number of subjects: 59
Study 21414045 — intervention group
Group type: COMPARATOR
Intervention: Inulin (control)
Number of subjects: 59
Study 19669067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group therapy (16 semi-structured sessions)
Number of subjects: 40
Study 19669067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group therapy
Number of subjects: 40
Study 17301114 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Baby Interaction Programme (PBIP)
Number of subjects: 233
Study 17301114 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 233
Study 15557491 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b (250 microg)
Number of subjects: 939
Study 15557491 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b (160 microg/m2)
Number of subjects: 939
Study 15557491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 939
Study 11485143 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride (monotherapy) at doses of 1.5-4.5 g once daily or in two divided doses
Number of subjects: 0
Study 11485143 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride combined with HMG-CoA reductase inhibitor
Number of subjects: 0
Study 11485143 — intervention group
Group type: COMPARATOR
Intervention: Colesevelam hydrochloride (monotherapy)
Number of subjects: 0
Study 11485143 — intervention group
Group type: COMPARATOR
Intervention: Colesevelam hydrochloride
Number of subjects: 0
Study 8988911 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT oil
Number of subjects: 9
Study 8988911 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm oil
Number of subjects: 9
Study 8988911 — intervention group
Group type: EXPERIMENTAL
Intervention: High oleic acid sunflower oil
Number of subjects: 9
Study 8097921 — intervention group
Group type: EXPERIMENTAL
Intervention: Abecarnil 20 mg
Number of subjects: 10
Study 8097921 — intervention group
Group type: EXPERIMENTAL
Intervention: Abecarnil 40 mg
Number of subjects: 10
Study 8097921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2880903 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine instillation
Number of subjects: 0
Study 2880903 — intervention group
Group type: COMPARATOR
Intervention: Normal saline instillation
Number of subjects: 0
Study 29868998 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral drug abuse treatment (intervention)
Number of subjects: 1305
Study 29868998 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1305
Study 26682749 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (800 IU/day) without exercise
Number of subjects: 409
Study 26682749 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo and exercise
Number of subjects: 409
Study 26682749 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (800 IU/day) with exercise
Number of subjects: 409
Study 26682749 — intervention group
Group type: COMPARATOR
Intervention: Placebo without exercise
Number of subjects: 409
Study 22943586 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse lavage therapy at 10 to 15 psi pressure
Number of subjects: 30
Study 22943586 — intervention group
Group type: COMPARATOR
Intervention: Moist betadine saline gauze dressings
Number of subjects: 30
Study 22519907 — intervention group
Group type: EXPERIMENTAL
Intervention: Premeal cycling at moderate intensity
Number of subjects: 0
Study 22519907 — intervention group
Group type: COMPARATOR
Intervention: Meal-only condition (control)
Number of subjects: 0
Study 20533373 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg rhFGF-2 (low-dosage group)
Number of subjects: 70
Study 20533373 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 mg rhFGF-2 (high-dosage group)
Number of subjects: 70
Study 20533373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 20533373 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dosage group
Number of subjects: 70
Study 20533373 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage group
Number of subjects: 70
Study 20533373 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 70
Study 18535816 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 8
Study 16422854 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil plus continuous testosterone undecanoate therapy (TRT) in group 1ST
Number of subjects: 40
Study 16422854 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil alone in group 2S
Number of subjects: 40
Study 16422854 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil plus continuous TRT for 2 months in group 2ST
Number of subjects: 40
Study 16422854 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate therapy (TRT) alone in group 1T
Number of subjects: 40
Study 12040138 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined interventions
Number of subjects: 78
Study 12040138 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational and psychotherapeutic interventions
Number of subjects: 78
Study 12040138 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions for dementia caregivers
Number of subjects: 78
Study 9801742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide aqueous pump spray (Rhinocort Aqua) 32 micrograms, 64 micrograms, 128 micrograms, 256 micrograms
Number of subjects: 406
Study 9801742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide aqueous pump spray (Rhinocort Aqua) 32 micrograms, 128 micrograms, 256 micrograms
Number of subjects: 406
Study 9801742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide aqueous pump spray (Rhinocort Aqua) 256 micrograms
Number of subjects: 406
Study 9801742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 9801742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide aqueous pump spray (Rhinocort Aqua)
Number of subjects: 406
Study 10155437 — intervention group
Group type: EXPERIMENTAL
Intervention: Actronics Interactive Learning System (IVD)
Number of subjects: 86
Study 10155437 — intervention group
Group type: COMPARATOR
Intervention: Traditional method of demonstration/return demonstration
Number of subjects: 86
Study 2788116 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 180
Study 2788116 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy alone
Number of subjects: 180
Study 324723 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphamethoxazole/trimethoprim (Bactrim)
Number of subjects: 30
Study 324723 — intervention group
Group type: COMPARATOR
Intervention: nitrofurantoin
Number of subjects: 30
Study 30998643 — intervention group
Group type: EXPERIMENTAL
Intervention: Prominent cannulated screws
Number of subjects: 20
Study 30998643 — intervention group
Group type: COMPARATOR
Intervention: Recessed cannulated screws
Number of subjects: 20
Study 30998643 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 28813007 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics formula containing Bifidobacterium longum BORI and Lactobacillus acidophilus AD031 (N = 28)
Number of subjects: 57
Study 28813007 — intervention group
Group type: COMPARATOR
Intervention: Placebo (probiotic‐free skim milk, N = 29)
Number of subjects: 57
Study 28813007 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics formula
Number of subjects: 57
Study 28813007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 25972527 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicatechin (100 mg/d)
Number of subjects: 37
Study 25972527 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (160 mg/d)
Number of subjects: 37
Study 25972527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 23585192 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight (BMI <25 kg/m²)
Number of subjects: 3017
Study 23585192 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (BMI ≥25 kg/m² and <30 kg/m²)
Number of subjects: 3017
Study 23585192 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese (BMI ≥30 kg/m²)
Number of subjects: 3017
Study 23585192 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab
Number of subjects: 3017
Study 20439105 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-year cardiovascular risk assessment by practice nurses
Number of subjects: 421
Study 19251200 — intervention group
Group type: EXPERIMENTAL
Intervention: PPTs ON
Number of subjects: 240
Study 19251200 — intervention group
Group type: COMPARATOR
Intervention: PPTs OFF
Number of subjects: 240
Study 16428266 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori eradication therapy (group 1, n = 41)
Number of subjects: 81
Study 16428266 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group 2, n = 40)
Number of subjects: 81
Study 15387976 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC(250) for 1 week (group A1)
Number of subjects: 248
Study 15387976 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC(250) for 2 weeks (group A2)
Number of subjects: 248
Study 15387976 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC(500) for 1 week (group B1)
Number of subjects: 248
Study 15387976 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC(500) for 2 weeks (group B2)
Number of subjects: 248
Study 15387976 — intervention group
Group type: EXPERIMENTAL
Intervention: OAM for 1 week (group C1)
Number of subjects: 248
Study 15387976 — intervention group
Group type: EXPERIMENTAL
Intervention: OAM for 2 weeks (group C2)
Number of subjects: 248
Study 15387976 — intervention group
Group type: COMPARATOR
Intervention: Successful Hp eradication
Number of subjects: 248
Study 15387976 — intervention group
Group type: COMPARATOR
Intervention: Unsuccessful Hp eradication
Number of subjects: 248
Study 11788000 — intervention group
Group type: EXPERIMENTAL
Intervention: Strand displacement amplification (SDA) in first‐catch urine (FCU) specimens from men
Number of subjects: 1006
Study 11788000 — intervention group
Group type: EXPERIMENTAL
Intervention: Strand displacement amplification (SDA) in first‐catch urine (FCU) specimens from women
Number of subjects: 1006
Study 11788000 — intervention group
Group type: EXPERIMENTAL
Intervention: Strand displacement amplification (SDA) in endocervical swab (ECS) specimens from women
Number of subjects: 1006
Study 11788000 — intervention group
Group type: COMPARATOR
Intervention: Ligase chain reaction (LCR)
Number of subjects: 1006
Study 9373743 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication course (4 weeks)
Number of subjects: 47
Study 9373743 — intervention group
Group type: COMPARATOR
Intervention: No further rehabilitation (control group)
Number of subjects: 47
Study 1348079 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha (1, 3, or 5 million units thrice weekly for 4 or 6 months)
Number of subjects: 12
Study 1348079 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha
Number of subjects: 12
Study 3886998 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, coumadin, and dipyridamole for 18 months
Number of subjects: 59
Study 3886998 — intervention group
Group type: COMPARATOR
Intervention: No specific therapy
Number of subjects: 59
Study 3886998 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, coumadin, and dipyridamole
Number of subjects: 59
Study 30650183 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Technique (CT)
Number of subjects: 157
Study 30650183 — intervention group
Group type: COMPARATOR
Intervention: Manual Technique (MT)
Number of subjects: 157
Study 28733284 — intervention group
Group type: EXPERIMENTAL
Intervention: FM‐CBAL74 (fermented cow's milk containing heat-killed Lactobacillus paracasei CBA L74)
Number of subjects: 20
Study 28733284 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study 26169336 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine
Number of subjects: 150
Study 26169336 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine
Number of subjects: 150
Study 23680059 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (INS)
Number of subjects: 0
Study 23680059 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (ROS)
Number of subjects: 0
Study 23680059 — intervention group
Group type: COMPARATOR
Intervention: Standard strategy targeting HbA1c to 7.0%-7.9% (53-63mmol/mol)
Number of subjects: 0
Study 23680059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive control targeting HbA1c to <6.0% (42mmol/mol)
Number of subjects: 0
Study 21646925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 21646925 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 194
Study 18312543 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine (4 mg daily for 6 days)
Number of subjects: 36
Study 18312543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 16550731 — intervention group
Group type: EXPERIMENTAL
Intervention: DOX GITS (4 mg/d)
Number of subjects: 310
Study 16550731 — intervention group
Group type: COMPARATOR
Intervention: DOX-S4 (4 mg/d)
Number of subjects: 310
Study 16550731 — intervention group
Group type: COMPARATOR
Intervention: DOX-S2 (2 mg/d)
Number of subjects: 310
Study 12606887 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1200 mg of elemental calcium daily)
Number of subjects: 617
Study 12606887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 617
Study 10960963 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise condition (50% maximal workload on the bicycle ergometer for four times 30 minutes during the first 6 hours) at 3000 m altitude
Number of subjects: 8
Study 10960963 — intervention group
Group type: COMPARATOR
Intervention: Sedentary condition at 3000 m altitude
Number of subjects: 8
Study 10960963 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise condition at 3000 m altitude
Number of subjects: 8
Study 10960963 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise condition at 171 m altitude
Number of subjects: 8
Study 10960963 — intervention group
Group type: COMPARATOR
Intervention: Sedentary condition at 171 m altitude
Number of subjects: 8
Study 8981304 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFNA (9 x 10(6) IU) intramuscularly every other day for 6 months
Number of subjects: 20
Study 1478293 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyadenylic-polyuridylic acid (AU), one i.v. injection of 60 mg (in 50 ml of solution) once a week for 6 weeks
Number of subjects: 288
Study 1478293 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P), one i.v. injection of 50 ml of saline solution with the same schedule
Number of subjects: 288
Study 1478293 — intervention group
Group type: COMPARATOR
Intervention: Overall survival comparison between AU and P groups
Number of subjects: 288
Study 6587756 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 64
Study 6587756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 3094463 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 90
Study 3094463 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium aurothiomalate
Number of subjects: 90
Study 3094463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 3094463 — intervention group
Group type: COMPARATOR
Intervention: Placebo (original group)
Number of subjects: 90
Study 29690924 — intervention group
Group type: EXPERIMENTAL
Intervention: Regularly dosed paracetamol
Number of subjects: 0
Study 29690924 — intervention group
Group type: COMPARATOR
Intervention: No paracetamol
Number of subjects: 0
Study 26199465 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Dexmedetomidine (DEX)
Number of subjects: 60
Study 23893147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiscal and intraforaminal injection of oxygen‐ozone
Number of subjects: 172
Study 23893147 — intervention group
Group type: COMPARATOR
Intervention: Injection of oxygen‐ozone combined with 1ml of compound betamethasone
Number of subjects: 172
Study 21912342 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthpiece use during exercise
Number of subjects: 28
Study 21912342 — intervention group
Group type: COMPARATOR
Intervention: No mouthpiece during exercise
Number of subjects: 28
Study 18829998 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (150 mg)
Number of subjects: 86
Study 18829998 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (1 mg)
Number of subjects: 86
Study 16773438 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy
Number of subjects: 0
Study 16773438 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 14604715 — intervention group
Group type: EXPERIMENTAL
Intervention: Microkeratome blades wiped with sterile 100% alcohol before LASIK
Number of subjects: 24
Study 14604715 — intervention group
Group type: COMPARATOR
Intervention: Control group with microkeratome blades wiped with balanced salt solution (BSS)
Number of subjects: 24
Study 10758928 — intervention group
Group type: EXPERIMENTAL
Intervention: 6Fr Techstar device
Number of subjects: 715
Study 10758928 — intervention group
Group type: EXPERIMENTAL
Intervention: 8Fr or 10Fr Prostar-Plus device
Number of subjects: 715
Study 10758928 — intervention group
Group type: COMPARATOR
Intervention: Traditional compression
Number of subjects: 715
Study 10758928 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture-mediated closure
Number of subjects: 715
Study 8742282 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 28
Study 8742282 — intervention group
Group type: COMPARATOR
Intervention: Intravenous regional anesthesia
Number of subjects: 28
Study 1428569 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 2% (n = 11)
Number of subjects: 43
Study 1428569 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 0.5% (n = 11)
Number of subjects: 43
Study 1428569 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 0.05% (n = 11)
Number of subjects: 43
Study 1428569 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 0.1% (n = 10)
Number of subjects: 43
Study 1428569 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 43
Study 6362409 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole
Number of subjects: 7
Study 6362409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30660602 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous endometrial cell co-culture (AECC)
Number of subjects: 136
Study 30660602 — intervention group
Group type: COMPARATOR
Intervention: Conventional embryo culture medium
Number of subjects: 136
Study 28275132 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFA) overfeeding (+750 kcal/d) for 7 weeks
Number of subjects: 31
Study 28275132 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFA) overfeeding (+750 kcal/d) for 7 weeks
Number of subjects: 31
Study 28275132 — intervention group
Group type: COMPARATOR
Intervention: Combined data from SFA and PUFA groups
Number of subjects: 31
Study 25850750 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag (400 μg single dose)
Number of subjects: 64
Study 25850750 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag (600 μg multiple doses)
Number of subjects: 64
Study 25850750 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag (400 μg open-label dose)
Number of subjects: 64
Study 25850750 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-333679 (active metabolite)
Number of subjects: 64
Study 25850750 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 64
Study 23944767 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsynonymous m.10398A>G mtDNA polymorphism (N=8)
Number of subjects: 39
Study 23944767 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplogroup H (N=13)
Number of subjects: 39
Study 23944767 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplogroup U (N=6)
Number of subjects: 39
Study 21827706 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin-piperaquine (AP)
Number of subjects: 220
Study 21827706 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine phosphate (DHP)
Number of subjects: 220
Study 21827706 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 220
Study 19259863 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer and physical activity message
Number of subjects: 200
Study 19259863 — intervention group
Group type: COMPARATOR
Intervention: Cardiovascular disease and physical activity message
Number of subjects: 200
Study 17223112 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 5mg
Number of subjects: 154
Study 17223112 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10mg
Number of subjects: 154
Study 17223112 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20mg
Number of subjects: 154
Study 17223112 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate 200mg
Number of subjects: 154